Showing 8561-8570 of 9142 results for "".
- Website Launches for Those Suffering from Acne Scarshttps://practicaldermatology.com/news/20141003-website_launches_for_those_suffering_from_acne_scars/2459097/A new website has launched to help those who suffer from the physical and emotional impacts of acne scarring. “A Scar Free Me” is the first of its kind online community that offers free resources and support for people coping with the aftermath of acne. Visitors can consult with skin car
- Teledermatology App Teams Up with Dermatologistshttps://practicaldermatology.com/news/20141002-teledermatology_company_teams_up_with_dermatologists/2459098/A new teledermatology app is partnering with board- and state-certified dermatologists to assist patients with on-the-spot information regarding the detection and evaluation of skin disease in early stages. Having launched already in 13 states, Klara has partnered up with Dr. Mark Kaufmann, MD, Asso
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Pacific Edge Granted US Patent for Melanoma Detectionhttps://practicaldermatology.com/news/20140905-pacific_edge_granted_us_patent_for_melanoma_detection/2459127/The United States Patent and Trademark Office granted Pacific Edge Limited, a cancer diagnostics company, US Patent Number 8,822,149 covering "Prognosis Prediction for Melanoma Cancer." The patent covers the technology being used to develop a melanoma prognostic test that will e